Abstract: The present invention relates to a combination of elafibranor with either riboflavin or DHA as antiviral agent. The bacteriophage T4 titer on E. coli that is increased by elafibranor in comparison to an untreated control is reversed by the combination of elafibranor with riboflavin or elafibranor with DHA. Therefore, these combinations decrease adverse side effects of elafibranor on the gut microbiota.

Abstract: A composition comprising ?-tocopherol acetate (also referred to as Vitamin E acetate “Vit E Acetate”) and docosahexaenoic acid ethyl ester (“DHA EE”), exhibits surprising oxidative stability.

Abstract: The present invention relates to compositions comprising a water soluble tomato extract (WSTE) which may be used in maintaining cardiovascular health, lessening the risk of developing cardiovascular health problems, or reducing the likelihood of worsening an existing cardiovascular health problem in a subject exposed, or is at risk of exposure, to particulate air pollution.

Abstract: The present invention relates to compositions comprising a water soluble tomato extract (WSTE) which may be used in maintaining cardiovascular health, lessening the risk of developing cardiovascular health problems, or reducing the likelihood of worsening an existing cardiovascular health problem in a subject exposed, or is at risk of exposure, to particulate air pollution.

Abstract: The present invention relates to the use of mixtures of vitamin E and polyunsaturated fatty acids (PUFAs) as agents for the prevention, control and/or treatment of conditions associated with excessive fat accumulation in the liver which is not caused by alcohol abuse. This includes prevention, control and/or treatment of non-alcoholic steatosis in the liver—known as non-alcoholic fatty liver disease (NAFLD)—and/or non-alcoholic steatohepatitis (NASH) in a subject in need thereof. In particular, the present invention relates to the use of such compounds comprising vitamin E acetate and DHA EE as active ingredients in the manufacture of medicaments for the prevention, control and/or treatment of conditions related to NAFLD.

Abstract: The present invention relates to systemic detoxification by using extracts of Withania somnifera (ashwagandha) and its Nrf2-activating components withaferin-A, 12-deoxywithastramonolide, and Quresimine A. When ingested, the transcription factor Nrf2, which is a crucial element in intracellular detoxification pathways, leads to elimination of potentially toxic compounds. In parallel, the expression of inflammatory cytokines is decreased. Therefore, the extract can be used to reduce the adverse effects of air pollution generally (and especially of particulate air pollution), which includes: cardiovascular problems, respiratory diseases, and chronic inflammation of tissues that come into contact with air borne particles.

Abstract: The present invention relates to compositions comprising a water soluble tomato extract (WSTE) which may be used in maintaining cardiovascular health, lessening the risk of developing cardiovascular health problems, or reducing the likelihood of worsening an existing cardiovascular health problem in a subject exposed, or is at risk of exposure, to particulate air pollution.

Abstract: The present invention relates to the use of mixtures of vitamin E and polyunsaturated fatty acids (PUFAs) as agents for the prevention, control and/or treatment of conditions associated with excessive fat accumulation in the liver which is not caused by alcohol abuse. This includes prevention, control and/or treatment of non-alcoholic steatosis in the liver—known as non-alcoholic fatty liver disease (NAFLD)—and/or non-alcoholic steatohepatitis (NASH) in a subject in need thereof. In particular, the present invention relates to the use of such compounds comprising vitamin E acetate and DHA EE as active ingredients in the manufacture of medicaments for the prevention, control and/or treatment of conditions related to NAFLD.

Abstract: Use of DIM and/or its derivatives for prevention, treatment and/or delay of age-related hearing loss in mammals.

Abstract: The present invention refers to coumarin ethers of the formula (I), wherein R1 is H, OH or (E)-3-methyl-but-2-enyl, R2 is selected from the group consisting of methyl, 3-(4,5-dihydro-5,5-dimethyl-4-furanon-2-yl)-2-(E/Z)-butenyl, (E/Z)-3,7-dimethylocta-2,6-dienyl, 7-hydroxy-3,7-dimethyl-2-octen-6-on-yl and (E/Z,E/Z)-11-acetyl-oxy-3,7,11,11-tetramethyl-undeca-2,7-dien-10-on-yl, R3 is H, R1 and R2O together for the group —O—C(C(?CH2)CH3)H—CH2—O— or the group —C(H)?C(H)—C(CH3)2—O— or R2O and R3 together form the group —O—C(H)(C(CH3)2(H)—O—C(O)CH3)—CH2—, preferably to obliquin, for use as medicaments, especially for the treatment and/or prevention of disorders connected to impaired neurotransmission, as well as to dietary and pharmaceutical compositions and plant extracts containing such coumarin ethers and their uses.

Abstract: Use of DIM and/or its derivatives for prevention, treatment and/or delay of age-related hearing loss in mammals.

Abstract: The invention relates to a novel nutraceutical composition containing Zanthoxlyum bungeanum whole-fruit extract as active ingredient. The term “nutraceutical” as used herein denotes usefulness in nutritional, pharmaceutical and veterinary fields of application. The compositions are useful for improvement of cognitive functions, such as learning, memory and alertness, psychotic stability and maintenance.

Abstract: The invention relates to a novel nutraceutical composition containing Stevia extract or its constituents, such as steviol and stevioside, as active ingredient(s). The term “nutraceutical” as used herein denotes usefulness in nutritional, pharmaceutical and veterinary fields of application. The compositions are useful for improvement of cognitive functions, such as learning, memory and alertness, and psychotic stability.

Abstract: The invention relates to a novel nutraceutical composition containing thymol and/or p-cymene, or a plant extract containing thymol or p-cymene as active ingredient(s). The compositions are useful for improvement of cognitive functions and psycho-social status, such as learning, memory and alertness, psychotic stability and maintenance.

Abstract: The present invention refers to coumarin ethers of the formula (I), wherein R1 is H, OH or (E)-3-methyl-but-2-enyl, R2 is selected from the group consisting of methyl, 3-(4,5-dihydro-5,5-dimethyl-4-furanon-2-yl)-2-(E/Z)-butenyl, (E/Z)-3,7-dimethylocta-2,6-dienyl, 7-hydroxy-3,7-dimethyl-2-octen-6-on-yl and (E/Z, E/Z)-1-acetyl-oxy-3,7,11,11-tetramethyl-undeca-2,7-dien-10-on-yl, R3 is H, R1 and R2O together for the group —O—C(C(?CH2)CH3)H—CH2—O— or the group —C(H)?C(H)—C(CH3)2—O— or R2O and R3 together form the group —O—C(H)(C(CH3)2(H)—O—C(O)CH3)—CH2—, preferably to obliquin, for use as medicaments, especially for the treatment and/or prevention of disorders connected to impaired neurotransmission, as well as to dietary and pharmaceutical compositions and plant extracts containing such coumarin ethers and their uses.